quinoxalines has been researched along with Lymphoma in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (14.29) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (71.43) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Bertoni, F; Lupia, A; Stathis, A; Tarantelli, C | 1 |
| Bethel, K; Cullen, BR; Jin, HY; Kang, SG; Lai, M; Liu, WH; Oda, H; Rajewsky, K; Sabouri-Ghomi, M; Shepherd, J; Skalsky, RL; Xiao, C | 1 |
| Abrisqueta, P; Bentzien, F; Egile, C; Jiang, J; Papadopoulos, KP; Rasco, D; Ruiz-Soto, R; Shi, W; Tabernero, J; Vose, JM | 1 |
| Abrisqueta, P; Awan, FT; Brown, JR; Davids, MS; Egile, C; Jiang, J; Kasar, SN; Lager, J; Rodon, J | 1 |
| Bechter, OE; Costermans, J; Dedieu, JF; Dumez, H; Francesconi, E; Ghuysen, AF; Hsu, K; Liu, L; Punie, K; Schöffski, P; Sharma, J | 1 |
| Cheng, G; Dai, M; Hao, H; Ihsan, A; Liu, Q; Liu, X; Luo, X; Wang, X; Yuan, Z; Zhang, J | 1 |
| Hasegawa, H; Ohgaki, H; Sato, S; Suenaga, M; Sugimura, T; Takayama, S | 1 |
1 review(s) available for quinoxalines and Lymphoma
| Article | Year |
|---|---|
Is There a Role for Dual PI3K/mTOR Inhibitors for Patients Affected with Lymphoma?
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Chromones; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma; Molecular Targeted Therapy; Oligopeptides; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinoxalines; Signal Transduction; Sulfonamides; TOR Serine-Threonine Kinases | 2020 |
3 trial(s) available for quinoxalines and Lymphoma
| Article | Year |
|---|---|
Efficacy, safety, pharmacokinetics and pharmacodynamics of SAR245409 (voxtalisib, XL765), an orally administered phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor: a phase 1 expansion cohort in patients with relapsed or refractory lymphoma
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anemia; Area Under Curve; Diarrhea; Drug Resistance, Neoplasm; Exanthema; Female; Humans; Lymphoma; Male; MAP Kinase Signaling System; Metabolic Clearance Rate; Middle Aged; Nausea; Neoplasm Recurrence, Local; Phosphoinositide-3 Kinase Inhibitors; Quinoxalines; Remission Induction; Sulfonamides; TOR Serine-Threonine Kinases; Treatment Outcome; Young Adult | 2015 |
Phase I Trial of the Pan-PI3K Inhibitor Pilaralisib (SAR245408/XL147) in Patients with Chronic Lymphocytic Leukemia (CLL) or Relapsed/Refractory Lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cohort Studies; Female; Humans; Kaplan-Meier Estimate; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma; Male; Middle Aged; Neoplasm Recurrence, Local; Phosphoinositide-3 Kinase Inhibitors; Quinoxalines; Sulfonamides | 2015 |
Phase I safety and pharmacokinetic dose-escalation study of pilaralisib polymorph E, a phosphoinositide 3-kinase inhibitor in tablet formulation, in patients with solid tumors or lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Capsules; Dose-Response Relationship, Drug; Female; Humans; Lymphoma; Male; Middle Aged; Neoplasms; Phosphoinositide-3 Kinase Inhibitors; Quinoxalines; Sulfonamides; Tablets | 2016 |
3 other study(ies) available for quinoxalines and Lymphoma
| Article | Year |
|---|---|
MicroRNA-17~92 plays a causative role in lymphomagenesis by coordinating multiple oncogenic pathways.
Topics: Animals; B-Lymphocytes; Burkitt Lymphoma; Cell Proliferation; Cell Survival; Gene Expression Regulation, Neoplastic; Homeodomain Proteins; Humans; Imidazoles; Lymphoma; Mice; Mice, Inbred C57BL; Mice, Transgenic; MicroRNAs; Morpholines; NF-kappa B; Phosphatidylinositol 3-Kinases; Quinoxalines; Reproducibility of Results; RNA, Long Noncoding | 2013 |
Further investigations into the genotoxicity of quinoxaline-di-N-oxides and their primary metabolites.
Topics: Animals; Chromosome Aberrations; Cyclic N-Oxides; DNA Damage; Dose-Response Relationship, Drug; Lymphoma; Mice; Micronucleus Tests; Mutagenicity Tests; Quinoxalines; Salmonella typhimurium | 2016 |
Carcinogenicity in mice of a mutagenic compound, 2-amino-3,8-dimethylimidazo[4,5-f]quinoxaline (MeIQx) from cooked foods.
Topics: Animals; Cooking; Female; Food Analysis; Leukemia, Experimental; Liver Neoplasms, Experimental; Lung Neoplasms; Lymphoma; Male; Mice; Mutagens; Neoplasms, Experimental; Quinoxalines | 1987 |